Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 32 |
| List of Tables | 29 | 4 |
| List of Figures | 33 | 1 |
| Introduction | 34 | 1 |
| Global Markets Direct Report Coverage | 34 | 1 |
| Obesity Overview | 35 | 1 |
| Therapeutics Development | 36 | 2 |
| Pipeline Products for Obesity Overview | 36 | 1 |
| Pipeline Products for Obesity Comparative Analysis | 37 | 1 |
| Obesity Therapeutics under Development by Companies | 38 | 10 |
| Obesity Therapeutics under Investigation by Universities/Institutes | 48 | 3 |
| Obesity Pipeline Products Glance | 51 | 4 |
| Late Stage Products | 51 | 1 |
| Clinical Stage Products | 52 | 1 |
| Early Stage Products | 53 | 1 |
| Unknown Stage Products | 54 | 1 |
| Obesity Products under Development by Companies | 55 | 12 |
| Obesity Products under Investigation by Universities/Institutes | 67 | 4 |
| Obesity Companies Involved in Therapeutics Development | 71 | 100 |
| Abeome Corporation | 71 | 1 |
| Acylin Therapeutics Inc | 72 | 1 |
| Advinus Therapeutics Ltd | 73 | 1 |
| Aegis Therapeutics, LLC | 74 | 1 |
| Akron Molecules AG | 75 | 1 |
| Alize Pharma SAS | 76 | 1 |
| Amabiotics SAS | 77 | 1 |
| Amgen Inc. | 78 | 1 |
| Aoxing Pharmaceutical Company, Inc | 79 | 1 |
| Arena Pharmaceuticals, Inc. | 80 | 1 |
| AstraZeneca Plc | 81 | 1 |
| Asubio Pharma Co., Ltd. | 82 | 1 |
| Athersys, Inc. | 83 | 1 |
| Biophytis SAS | 84 | 1 |
| BioRestorative Therapies, Inc. | 85 | 1 |
| Boehringer Ingelheim GmbH | 86 | 1 |
| Braasch Biotech LLC | 87 | 1 |
| C3 Jian, Inc | 88 | 1 |
| Carmot Therapeutics Inc | 89 | 1 |
| Chronos Therapeutics Limited | 90 | 1 |
| CohBar, Inc. | 91 | 1 |
| CoMentis, Inc. | 92 | 1 |
| Connexios Life Sciences Pvt. Ltd. | 93 | 1 |
| Corium International, Inc. | 94 | 1 |
| Daiichi Sankyo Company, Limited | 95 | 1 |
| Diabetica Limited | 96 | 1 |
| DiscoveryBiomed, Inc. | 97 | 1 |
| Eli Lilly and Company | 98 | 1 |
| Esperion Therapeutics, Inc. | 99 | 1 |
| Eternygen GmbH | 100 | 1 |
| Evotec AG | 101 | 1 |
| F. Hoffmann-La Roche Ltd. | 102 | 1 |
| FibroGen Inc | 103 | 1 |
| Galenea Corp. | 104 | 1 |
| Gila Therapeutics Inc | 105 | 1 |
| Gilead Sciences, Inc. | 106 | 1 |
| GlaxoSmithKline Plc | 107 | 1 |
| GTx, Inc. | 108 | 1 |
| HanAll Biopharma Co., Ltd. | 109 | 1 |
| Handok Inc. | 110 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 111 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 112 | 1 |
| Immungenetics AG | 113 | 1 |
| Intarcia Therapeutics, Inc. | 114 | 1 |
| Ionis Pharmaceuticals, Inc. | 115 | 1 |
| Ixchel Pharma, LLC | 116 | 1 |
| Jenrin Discovery, Inc. | 117 | 1 |
| Johnson &Johnson | 118 | 1 |
| Kowa Company, Ltd. | 119 | 1 |
| Lead Discovery Center GmbH | 120 | 1 |
| Leading BioSciences, Inc. | 121 | 1 |
| LEO Pharma A/S | 122 | 1 |
| LG Life Science LTD. | 123 | 1 |
| Lotus Pharmaceutical Co., Ltd. | 124 | 1 |
| M Pharmaceutical Inc. | 125 | 1 |
| Magnus Life Ltd | 126 | 1 |
| MAKScientific, LLC | 127 | 1 |
| MedImmune LLC | 128 | 1 |
| Merck &Co., Inc. | 129 | 1 |
| Mitochon Pharmaceuticals, Inc. | 130 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 131 | 1 |
| NeuroNano Pharma Inc | 132 | 1 |
| NGM Biopharmaceuticals, Inc. | 133 | 1 |
| NIBEC | 134 | 1 |
| Nordic Bioscience A/S | 135 | 1 |
| Novo Nordisk A/S | 136 | 1 |
| ObeTherapy Biotechnology | 137 | 1 |
| Ogeda SA | 138 | 1 |
| Omeros Corporation | 139 | 1 |
| OPKO Biologics Ltd | 140 | 1 |
| OPKO Health, Inc. | 141 | 1 |
| Orbis Biosciences Inc | 142 | 1 |
| Orexigen Therapeutics, Inc. | 143 | 1 |
| Pfizer Inc. | 144 | 1 |
| PharmaIN Corporation | 145 | 1 |
| Poxel SA | 146 | 1 |
| Progenra, Inc. | 147 | 1 |
| Prometheon Pharma, LLC | 148 | 1 |
| ReCyte Therapeutics, Inc. | 149 | 1 |
| Renova Therapeutics Inc | 150 | 1 |
| Reviva Pharmaceuticals Inc. | 151 | 1 |
| Saniona AB | 152 | 1 |
| Sanofi | 153 | 1 |
| Selvita S.A. | 154 | 1 |
| Seoul Pharma Co., Ltd. | 155 | 1 |
| Shionogi &Co., Ltd. | 156 | 1 |
| Sinil Pharmaceutical Co., Ltd | 157 | 1 |
| Sorrento Therapeutics Inc | 158 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 159 | 1 |
| Takeda Pharmaceutical Company Limited | 160 | 1 |
| Toray Industries, Inc. | 161 | 1 |
| Umecrine AB | 162 | 1 |
| Vicore Pharma AB | 163 | 1 |
| Viking Therapeutics, Inc. | 164 | 1 |
| WhanIn Pharmaceutical Co., Ltd. | 165 | 1 |
| Xenetic Biosciences (UK) Limited | 166 | 1 |
| XL-protein GmbH | 167 | 1 |
| Yuyu Pharma, Inc. | 168 | 1 |
| Zafgen Inc. | 169 | 1 |
| Zealand Pharma A/S | 170 | 1 |
| Obesity Therapeutics Assessment | 171 | 22 |
| Assessment by Monotherapy Products | 171 | 1 |
| Assessment by Combination Products | 172 | 1 |
| Assessment by Target | 173 | 8 |
| Assessment by Mechanism of Action | 181 | 8 |
| Assessment by Route of Administration | 189 | 2 |
| Assessment by Molecule Type | 191 | 2 |
| Drug Profiles | 193 | 302 |
| (acarbose + orlistat) Drug Profile | 193 | 1 |
| (bupropion hydrobromide SR + zonisamide SR) Drug Profile | 194 | 2 |
| (liraglutide + setmelanotide) Drug Profile | 196 | 1 |
| (metoprolol + tesofensine) Drug Profile | 197 | 2 |
| 18-MC Drug Profile | 199 | 1 |
| Adiponectin Secretagogue Drug Profile | 200 | 1 |
| AKR-101 Drug Profile | 201 | 1 |
| AKR-102 Drug Profile | 202 | 1 |
| AM-6545 Drug Profile | 203 | 1 |
| AM-833 Drug Profile | 204 | 1 |
| AMA-201 Drug Profile | 205 | 1 |
| Antisense Oligonucleotide to Inhibit ACC2 for Obesity Drug Profile | 206 | 1 |
| Antisense Oligonucleotide to Inhibit miR-33 for Obesity Drug Profile | 207 | 2 |
| Antisense RNAi Oligonucleotide to Inhibit Apobec-1 for Obesity Drug Profile | 209 | 1 |
| AV-3208 Drug Profile | 210 | 1 |
| AZ-12861903 Drug Profile | 211 | 1 |
| AZ-13483342 Drug Profile | 212 | 1 |
| AZD-3857 Drug Profile | 213 | 1 |
| AZP-531 Drug Profile | 214 | 3 |
| BI-186908 Drug Profile | 217 | 1 |
| BIO-101 Drug Profile | 218 | 2 |
| Biologics for Obesity Drug Profile | 220 | 1 |
| Biologics for Type 2 Diabetes and Obesity Drug Profile | 221 | 1 |
| BSN-881 Drug Profile | 222 | 1 |
| C-21 Drug Profile | 223 | 2 |
| canagliflozin Drug Profile | 225 | 7 |
| CAS-001 Drug Profile | 232 | 1 |
| CAS-003 Drug Profile | 233 | 1 |
| cerium oxide Drug Profile | 234 | 1 |
| CNIO-PI3Ki Drug Profile | 235 | 1 |
| CNX-013B2 Drug Profile | 236 | 1 |
| CV-0801 Drug Profile | 237 | 1 |
| CV-0802 Drug Profile | 238 | 1 |
| dapagliflozin propanediol Drug Profile | 239 | 7 |
| DLN-200 Drug Profile | 246 | 1 |
| DLN-300 Drug Profile | 247 | 1 |
| DLN-400 Drug Profile | 248 | 1 |
| DPR-211 Drug Profile | 249 | 1 |
| Drug to Target Protein Phosphatase 5 for Obesity Drug Profile | 250 | 1 |
| Drugs for Obesity Drug Profile | 251 | 1 |
| Drugs for Obesity Drug Profile | 252 | 1 |
| Drugs to Antagonize GABA A Receptor for Obesity Drug Profile | 253 | 1 |
| Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders Drug Profile | 254 | 1 |
| DSP-0011 Drug Profile | 255 | 1 |
| E-6 Drug Profile | 256 | 1 |
| efpeglenatide Drug Profile | 257 | 2 |
| efpeglenatide + HM-12470 Drug Profile | 259 | 1 |
| englerin A Drug Profile | 260 | 1 |
| ESI-05 Drug Profile | 261 | 1 |
| ESN-700 Drug Profile | 262 | 1 |
| ESP-41091 Drug Profile | 263 | 1 |
| exenatide + ND-017 Drug Profile | 264 | 1 |
| exenatide + Synthetic Peptide 1 Drug Profile | 265 | 1 |
| exenatide + Synthetic Peptide 2 Drug Profile | 266 | 1 |
| FG-4497 Drug Profile | 267 | 1 |
| FGH-10019 Drug Profile | 268 | 1 |
| fumagillin Drug Profile | 269 | 1 |
| G-3215 Drug Profile | 270 | 1 |
| G-530L Drug Profile | 271 | 1 |
| Gene Therapy for Obesity and Type 2 Diabetes Drug Profile | 272 | 1 |
| Gly-MCA Drug Profile | 273 | 1 |
| GMC-278 Drug Profile | 274 | 1 |
| GO-CoA-Tat Drug Profile | 275 | 1 |
| GSK-2041706 Drug Profile | 276 | 1 |
| GT-001 Drug Profile | 277 | 1 |
| GT-002 Drug Profile | 278 | 1 |
| GTS-21 Drug Profile | 279 | 2 |
| GTx-878 Drug Profile | 281 | 1 |
| HIS-388 Drug Profile | 282 | 1 |
| HL-271 Drug Profile | 283 | 1 |
| HL-5201 Drug Profile | 284 | 1 |
| HM-12525A Drug Profile | 285 | 1 |
| HOB-060 Drug Profile | 286 | 1 |
| HTB-006 Drug Profile | 287 | 1 |
| IC-7 Drug Profile | 288 | 1 |
| INV-88 Drug Profile | 289 | 1 |
| IONIS-463588 Drug Profile | 290 | 1 |
| ITE Drug Profile | 291 | 1 |
| IXC-301 Drug Profile | 292 | 1 |
| IXC-303 Drug Profile | 293 | 1 |
| IXC-305 Drug Profile | 294 | 1 |
| JD-0100 Series Drug Profile | 295 | 1 |
| JD-0200 Series Drug Profile | 296 | 1 |
| JD-0300 Series Drug Profile | 297 | 1 |
| JD-2000 Series Drug Profile | 298 | 1 |
| JD-5000 Series Drug Profile | 299 | 1 |
| JD-5006 Drug Profile | 300 | 1 |
| JD-5037 Drug Profile | 301 | 1 |
| JD-6000 Series Drug Profile | 302 | 1 |
| KBP-042 Drug Profile | 303 | 2 |
| KDTC-0D Drug Profile | 305 | 1 |
| KH-064 Drug Profile | 306 | 1 |
| KR-66344 Drug Profile | 307 | 1 |
| KR-69530 Drug Profile | 308 | 1 |
| liothyronine Drug Profile | 309 | 1 |
| LLY-2707 Drug Profile | 310 | 1 |
| lorcaserin hydrochloride Drug Profile | 311 | 9 |
| lorcaserin hydrochloride Drug Profile | 320 | 1 |
| LS-102 Drug Profile | 321 | 1 |
| MB-11055 Drug Profile | 322 | 1 |
| MB-12066 Drug Profile | 323 | 1 |
| MEDI-0382 Drug Profile | 324 | 1 |
| MOD-6030 Drug Profile | 325 | 1 |
| MOD-6031 Drug Profile | 326 | 1 |
| Monoclonal Antibodies for Obesity Drug Profile | 327 | 1 |
| Monoclonal Antibody to Inhibit Ghrelin for Obesity Drug Profile | 328 | 1 |
| montbretin A Drug Profile | 329 | 1 |
| MOTS-c Drug Profile | 330 | 1 |
| MP-301 Drug Profile | 331 | 1 |
| myonectin Drug Profile | 332 | 1 |
| ND-630 Drug Profile | 333 | 2 |
| NGM-313 Drug Profile | 335 | 1 |
| NGM-386 Drug Profile | 336 | 1 |
| NGM-395 Drug Profile | 337 | 1 |
| NM-4C16 Drug Profile | 338 | 1 |
| NN-9536 Drug Profile | 339 | 1 |
| NN-9747 Drug Profile | 340 | 1 |
| NNC-92041177 Drug Profile | 341 | 1 |
| NP-201 Program Drug Profile | 342 | 1 |
| NXCS-201 Drug Profile | 343 | 1 |
| OB-3 Drug Profile | 344 | 1 |
| OBE-2001 Drug Profile | 345 | 1 |
| ORB-203 Drug Profile | 346 | 1 |